Skip to main content
Bioinformation logoLink to Bioinformation
. 2025 Aug 31;21(8):2278–2281. doi: 10.6026/973206300212278

Expression of an intron-containing gene from P. falciparum using three sequential PCR steps

Ameer Abbas 1,*, Manoj Yadav 1,*, Vikas Kumar 1,*, Ankit Gupta 1,*
PMCID: PMC12697461  PMID: 41393482

Abstract

The amplification of eukaryotic genes, with introns is very tedious and expensive. The only available lab method is through cDNA synthesis, which has a very low success rate in generating a pure gene fragment. Therefore, it is of interest to devise a strategy to amplify a P. falciparum RPL12mito gene (PfRPL12mito) containing an intron through three sequential PCR steps using genomic DNA (gDNA) and primers with a minimum 15 bp 5'-overhang. The absence of an intronic segment and a continuous exonic region in the amplified gene fragment was confirmed using Sanger sequencing.

Keywords: Intron, Exon, cDNA, gene expression, PCR amplification, P. falciparum

Background:

Splicing is a key step during the expression of eukaryotic genes containing introns which encompass the removal of introns and joining of adjacent exons [1]. In vitro expression of gene containing introns involves the synthesis of cDNA from RNA through reverse transcription using oligo (dT) primers [2]. The complete removal of genomic DNA (gDNA) contamination from cDNA before PCR amplification is a prerequisite for either recombinant protein expression or protein overexpression [3]. Mild DNase treatment of cDNA often leaves trace amounts of genomic DNA, leading to the unintended amplification of gene fragments containing intronic regions [4]. In contrast, harsh DNase treatment compromises cDNA quality, resulting in little to no amplification of intron-free gene fragments [5]. Therefore, the amplification of gene fragments without introns from cDNA is mostly expensive, tedious, exhaustive, and unfeasible [6]. The alternative ways are either outsourced gene or dsDNA (G-blocks) synthesis, but both are expensive and time-consuming approaches [7]. Therefore, it is of interest to develop a method to amplify a gene fragment lacking an intron without cDNA synthesis.

Materials and Methods:

Parasite culture:

P. falciparum (3D7) parasites were cultivated at 37°C under 5% O2, 5% CO2, 90% N2 in O+ human erythrocytes, RPMI 1640 (Invitrogen) supplemented with 25 mM HEPES, 50 µg/ml hypoxanthine, 0.5% albumax (Gibco), and 0.23% NaHCO3. phenol-chloroform method.

Primer design, gDNA isolation and PCR amplification:

The reference sequence of Plasmodium falciparum RPL12mito gene (PF3D7_0212200; PfRPL12mito) was retrieved from PlasmoDB site (http://PlasmoDB.org) which contained a single intron (147bp) towards 3'-end followed by exon2 (71 bp). The primers were designed based on vector map (SnapGene) of the pET28a vector with the PfRPL12mito sequence containing an intron. The strategy was devised to amplify the full-length PfRPL12mito gene fragment (765 bp) without an intron through three sequential PCR steps without synthesizing cDNA (Figure 1 - see PDF). Four sequence-specific primers were developed and designated as p1, p2, p3, and p4, which contained 5-overhang complementary to the vector or PfRPL12mito gene sequence as given in Table 1 (see PDF). The length of primers p1, p2, and p3 was 45 bp; whereas, the p4 primer was 50 bp long. Genomic DNA (gDNA) was isolated from In vitro blood-stage P. falciparum (3D7) parasites (predominantly in the trophozoite stage) using the Quick-DNA MiniPrep kit (ZYMO Research) and used as a template for PCR1-3 as a reference (Figure 2a - see PDF). PCR1 amplification (736 bp) was done with primers (p1 and p2) using parasite gDNA (10ng/reaction) and SpeedSTAR HS DNA polymerase (Takara) at an annealing temperature of 62.4°C. The PCR product was purified by NucleoSpin PCR clean-up kit (Macherey-Nagel) and used as template for PCR2 (769 bp) with primers (p1 and p3) at an annealing temperature of 60.2°C. At last, PCR3 (807 bp) was done with purified PCR2 as a template using primers (p1 and p4) at an annealing temperature of 62.4°C (Figure 2b - see PDF).

Molecular cloning and recombinant protein expression:

PCR3 was cloned in the pET28a expression vector at BamHI and XhoI sites using the HD Infusion cloning kit (Takara), and clones were confirmed through restriction digestion with the same restriction enzymes, yielding bands of ~5.3kb and 771bp (Figure 2c - see PDF). The sequence of PfRPL12mito encompassing exons 1 and 2, and lacking the intronic segment in plasmid clones was further confirmed by Sanger sequencing (Figure 2d - see PDF). The plasmid clone was co-transformed with the RIG plasmid into BL21 (DE3) cells to express recombinant PfRPL12mito encompassing both n- and c-terminal 6xHis tag, respectively. The expression of recombinant PfRPL12mito protein (~35 kDa) was confirmed by western blotting using anti-His tag antibody (Sigma; 1:1000 dilution) and 3, 3-Diaminobenzidine (Sigma) (Figure 3 - see PDF).

Results:

Our method strategy bypasses tedious and expensive steps of synthesizing RNA, followed by cDNA synthesis. In most cases, cDNA either retains genomic DNA contamination despite DNase treatment or undergoes degradation with rigorous DNase treatment; both scenarios lead to poor or no amplification of the desired intron-free gene fragment. Consequently, cDNA-based gene amplification often fails or requires multiple attempts to achieve successful protein expression. Alternative approaches, such as dsDNA cloning or gene synthesis, are typically expensive and time-consuming. Here, a method has been devised to PCR-amplify intron-containing genes directly from eukaryotic genomes, such as Plasmodium falciparum, for protein expression purposes. We successfully amplified the PfRPL12mito gene fragment encompassing only exons and no intron through three sequential PCR steps with primers containing 5'overhang (Figure 1 - see PDF). Primer p2 was designed in such a way that it contained 3' ends (30 bp) homologous to exon 1 and a 5' overhang (15 bp) homologous to the exon 2 segment. PCR1 was the key step for this strategy to PCR amplify a gene fragment lacking an intronic segment, which was further used as a template for PCR2 (Figure 2a-b - see PDF). Thereafter, PCR2 was used as template to amplify the full-length PfRPL12mito gene (PCR3), which was cloned in the pET28a expression vector at BamHI and XhoI sites (Figure 2c - see PDF). Sanger sequencing of the resulting full-length PfRPL12mito gene fragment confirmed the lack of intron and presence of exons 1 and 2, both in frame and in continuation (Figure 2d - see PDF). Furthermore, the western blotting confirmed the successful expression of full-length PfRPL12mito protein with a 6xHis tag (Figure 3 - see PDF).

Discussion:

Traditional approaches for expressing eukaryotic genes involve the isolation of RNA followed by reverse transcription to cDNA. However, these steps are not only labour-intensive and costly but also suffer from technical limitations. A significant concern is the persistent contamination of cDNA with genomic DNA despite DNase treatment, or conversely, the degradation of cDNA under harsh DNase conditions. Both outcomes hinder the amplification of clean, intron-free gene fragments required for accurate protein expression. Additionally, alternatives such as dsDNA cloning or commercial gene synthesis, although effective, are resource-intensive and not always accessible, especially in resource-limited settings. To address these challenges, we developed a streamlined method for direct PCR amplification of intron-free gene fragments from eukaryotic genomes, e.g. Plasmodium falciparum. A key aspect of this strategy is the use of sequential PCR steps with primers designed to bridge exon-exon junctions. Specifically, the second primer (p2) incorporates a 3' region homologous to exon 1 and a 5' overhang homologous to exon 2, facilitating the seamless exclusion of intronic regions during amplification. This eliminates the need for RNA processing and ensures that only exonic sequences are retained in the final product. Furthermore, the successful amplification of the PfRPL12mito gene fragment comprising only exons was validated through Sanger sequencing. The sequence continuity and correct frame alignment of exons 1 and 2 demonstrate the accuracy of the amplification strategy. Importantly, western blot analysis verified the expression of full-length PfRPL12mito protein tagged with 6xHis, further substantiating the functional relevance of this approach. This method presents several key advantages: (i) it bypasses RNA extraction and reverses transcription, (ii) avoids the risk of intron retention or incomplete splicing, (iii) is more economical and time-efficient than gene synthesis and (iv) is broadly applicable to other eukaryotic genes with known exon-intron boundaries. It is especially valuable for organisms with high AT-rich content or where RNA is difficult to isolate, such as Plasmodium falciparum. Overall, the method provides a robust and accessible alternative for gene amplification and expression studies.

Conclusion:

We describe an efficient PCR-based method to amplify and express eukaryotic genes containing introns without relying on RNA extraction or cDNA synthesis. By circumventing the challenges associated with genomic DNA contamination and cDNA degradation, our strategy offers a cost-effective, time-saving, and reliable alternative to conventional approaches. The successful amplification, sequencing, and expression of the intron-free PfRPL12mito gene fragment from the Plasmodium falciparum genome validated the utility and robustness of this approach. However, the strategy has certain limitations, particularly its applicability only to genes containing a single intron.

Abbreviations:

cDNA - Complementary DNA

gDNA - Genomic DNA

RNA - Ribonucleic acid

PCR - Polymerase chain reaction

RPL - Ribosomal Protein Large Subunit

Pf - Plasmodium falciparum

Ethics approval:

The study includes the work which was duly approved by both the Institutional Ethics Committee (2024 -1- EMP- 8) and the Institutional Biosafety Committee (IBSC-2024-1-EMP-03).

Funding Statement:

The work is funded by a project grant (CST/D-896) received from the Council of Science and Technology (CST), Uttar Pradesh.

Consent to publish:

Not applicable

Data availability:

All relevant data are within the manuscript and its Supporting Information files.

Acknowledgments

We acknowledge the Department of Transfusion Medicine & Blood Bank for providing fresh erythrocytes for Plasmodium culture, and MRU lab at AIIMS, Raebareli.

The authors declare that they have no competing interests linked with the work reported in this paper.

Edited by P Kangueane

Citation: Abbas et al. Bioinformation 21(8):2278-2281(2025)

Declaration on Publication Ethics: The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail: The corresponding author declares that official e-mail from their institution is not available for all authors.

License statement: This is an Open Access article which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers: Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Bioinformation Impact Factor:Impact Factor (Clarivate Inc 2023 release) for BIOINFORMATION is 1.9 with 2,198 citations from 2020 to 2022 taken for IF calculations.

Disclaimer:The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required. Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain.

References

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All relevant data are within the manuscript and its Supporting Information files.


Articles from Bioinformation are provided here courtesy of Biomedical Informatics Publishing Group

RESOURCES